Background
Methods
Search strategy
PICO criteria
Population
Intervention
Comparison
Outcome
Inclusion and exclusion criteria
Study selection
Data extraction
Bias risk assessment, quality, and validity of included studies
PAPERS | Country | Year | JOURNAL | NEWCASTLE–OTTAWA SCALE (TOTAL SCORE) |
---|---|---|---|---|
ALAM ET AL. | India | 2019 | INDIAN HEART JOURNAL | 8 |
CHEN ET AL. | China | 2019 | ECHOCARDIOGRAPHY | 8 |
CHEN ET AL. | China | 2022 | JOURNAL OF HEALTHCARE ENGINEERING | 8 |
CRUZ ET AL | Portugal | 2019 | CLINICAL RESEARCH IN CARDIOLOGY | 8 |
GUAN ET AL. | Italy | 2021 | FRONTIERS IN PHARMACOLOGY | 8 |
HONG.K ET AL | China | 2013 | JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY | 7 |
HOU ET AL. | China | 2018 | JOURNAL OF HAINAN MEDICAL UNIVERSITY | 7 |
KARAKULAK ET AL | Turkey | 2020 | CARDIOVASCULAR TOXICOLOGY | 6 |
LI. ET AL. | China | 2019 | INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING | 6 |
MIHALCEA ET AL. | Romania | 2020 | NATURE, SCIENTIFIC REPORTS | 8 |
MIYOSHI. T ET AL. | Jaban | 2014 | ECHOCARDIOGRAPHY | 7 |
MORNOS C ET AL. | Greece | 2014 | HELLENIC JOURNAL OF CARDIOLOGY | 8 |
PIVETA. R ET AL. | Brazil | 2022 | FRONTIERS IN CARDIOVASCULAR MEDICINE | 8 |
SANTORO ET AL. | Italy | 2017 | EUROPEAN HEART JOURNAL CARDIOVASCULAR IMAGING | 8 |
SONG F ET AL. | China | 2017 | CARDIOLOGY JOURNAL | 7 |
SONG F ET AL. | China | 2017 | INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING | 7 |
WANG, Y. ET AL. | China | 2020 | INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING | 8 |
WANG, Y. ET AL. | China | 2020 | INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING | 8 |
XU ET AL. | China | 2019 | INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING | 8 |
XU ET AL. | China | 2021 | INTERNATIONAL JOURNAL OF GENERAL MEDICINE | 8 |
ZHANG ET AL. | USA- | 2018 | JACC: CARDIOVASCULAR IMAGING | 9 |
ZHAO ET AL. | China | 2020 | JACC: CARDIOONCOLOGY | 8 |
Results
REFERRENCES | COUNTRY | YEAR | NUMBER | AGE (YEARS) | TYPE OF CANCER | CHEMOTHERAPY PROTOCOL | VENDOR | WORK STATION |
---|---|---|---|---|---|---|---|---|
ALAM ET AL. | India | 2019 | 46 patients | 44.17 ± 10.95 | Various tumour types | Doxorubicin regimen | Vivid E9, GE | EchoPac PC |
CHEN ET AL. | China | 2019 | 83 patients | 49.25 ± 8.75 | Breast cancer | Epirubicin + cyclophosphamide regimen | GE Vivid E9 | EchoPac PC |
CHEN ET AL. | China | 2022 | 39 patients | 52.63 ± 9.28 | Multiple myeloma | 6 PAD regimen (bortezomib + Doxorubicin + dexamethasone) | Vivid E9, GE | EchoPac PC |
CRUZ ET AL | Portugal | 2019 | 105 patients | 53.8 ± 12.5 | Breast cancer | Anthracycline regimen | GE Vivid E9 orE95 | EchoPac PC |
GUAN ET AL. | Italy | 2021 | 79 patients | 48 ± 11.5 | Breast cancer | Different chemotherapeutic regimens | GE Vivid E95 | EchoPac PC |
HONG.K ET AL | China | 2013 | 53 survivors and 38 control | 18.6 ± 5.1 | Various tumour types | Anthracycline regimen | Artida, Toshiba | Advanced cardiology Package, Toshiba Medical Systems |
HOU ET AL. | China | 2018 | 58 patient- and 50 control | 45–65 | Lung cancer | Pemetrexed + cisplatin regimen | Philips X3-1 | TomTec 4D LV analysis |
KARAKULAK ET AL | Turkey | 2020 | 37 patients and 50 control | 53.5 ± 11.5 | Chronic Myeloid Leukaemia | Dasatinib or nilotinib after imatinib failure | GE Vivid E9 | Echo Pac PC |
LI. ET AL. | China | 2019 | 83 survivors and 42 control | 25.6 ± 6.1 | Various tumour types | Anthracycline regimen | Vivid, E95 | Echo Pac PC |
MIHALCEA ET AL. | Romania | 2020 | 110 NHL patients | 58 ± 11 | Non-Hodgkin’s lymphoma | CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) regimen | GE Vivid E9 | Echo Pac PC |
MIYOSHI. T ET AL. | Jaban | 2014 | 50 survivors and 20 control | 54 ± 15 | Various tumour types | Anthracycline regimen | Artida, Toshiba | Advanced cardiology Package, Toshiba Medical Systems |
MORNOS C ET AL. | Greece | 2014 | 59 patients | 50 ± 12 | Various tumour types | Anthracycline regimen | GE Vivid E9 | Echopac PC |
PIVETA. R ET AL. | Brazil | 2022 | 51 patients | 50.6 ± 11 | Breast cancer | (Doxorubicin + cyclophosphamide + trastuzumabin) regimen | Toshiba Artida | Advanced cardiology Package, Toshiba Medical Systems |
SANTORO ET AL. | Italy | 2017 | 100 patients | 48.6 ± 11.1 | Breast cancer | ANT and cyclophosphamide and/or 5-fluorouracil for 3–4 cycles | GE Vivid E9 | Echopac PC |
SONG F ET AL. | China | 2017 | 101 patients | 49 | Large B cell lymphoma | R- CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) regimen | IE 33, philips | TomTec 4D LV analysis |
SONG F ET AL. | China | 2017 | 89 Patients | 20 – 78 | Diffuse non-Hodgkin lymphoma | Anthracycline regimen | IE 33, philips | TomTec 4D LV analysis |
WANG ET AL. | China | 2020 | 64 patient 32 of them as a control group | 33.2 ± 8.3 | Breast cancer | Regular CTF followed by dexrazoxane and control group without dexrazoxane | Toshiba Artida SSH-880CV | Advanced cardiology Package, Toshiba Medical Systems |
WANG, Y. ET AL. | China | 2020 | 30 patients | 37—64 | Colorectal cancer | mFOLFOX6 regimen | GE Vivid E9 | Echopac PC |
XU ET AL. | China | 2019 | 60 patients | 49.3 ± 12.5 | large B-cell lymphoma | R- CHOP regimen | IE 33, Philips | TomTec 4D analysis |
XU ET AL. | China | 2021 | 95 patients | 53.2 ± 8.7 | Breast cancer | Epirubicin | GE Vivid E9 | Echopac PC |
ZHANG ET AL. | USA- | 2018 | 142 patient and 21 control | 41—56 | Breast cancer | Doxorubicin + cyclophosphamide followed by paclitaxel with or without trastuzumab | GE Vivid E9 or E7 | TomTec 4D LV analysis |
ZHAO ET AL. | China | 2020 | 74 patients | 48.9 ± 11.8 | Diffuse large B cell lymphoma | Anthracycline regimen | IE 33, Philips | TomTec 4D RV analysis |
REFERRENCES | 3D STI PARAMETERS | ECHO TIMING | KEY FINDING | PROGNOSIS |
---|---|---|---|---|
ALAM ET AL. | GLS, GCS, GRS, GAS, and 3D EF | baseline and after 4 cycles | all 3D strain parameters were significantly reduced after chemotherapy | No patients developed CTRCD |
CHEN ET AL. | GAS, GLS, GCS and GRS | 4 groups at 0,120 mg/m, 240 mg/m and at the end of chemotherapy 360 mg/m2 | GAS derived from 3D‐STI was more accurate and sensitive in responding to myocardial damage than other strain parameters and LVEF with significant negative correlation with anthracycline doses | No patients developld CTRCD |
CHEN ET AL. | LV GLS, GCS, GRS and RV GLS, GCS, GRS | Baseline and after cycle 2, 4 and 6 | RVGCS, RVGLS, RVGRS, LVGLS, and LVGRS in significantly reduced in patients before and after chemotherapy | No patients developed CTRCD |
CRUZ ET AL. | GLS, GCS, GRS, and GAS | baseline, during and after chemotherapy | significant worsening of all 3D strain parameters during chemotherapy. Variations of 3D GCS and 3D GRS had a good discrimination for predicting CTRCD | 24 patients developed CTRCD during follow up |
GUAN ET AL. | GLS, GCS, GAS, and GRS | before chemotherapy and after the cycle 2 (T2), cycle 4 (T4), cycle 6 (T6), and cycle 8 (T8) | all 3D strain parameters were significantly reduced at every stage of chemotherapy | 9of 79 patent developed CTRCD at different stages of chemotherapy |
HONG.K ET AL. | Global and segmental strain, SDI, GPI, and Torsion | survivors off treatment for more than 1 year | all 3D strain parameters were significantly reduced in cancer survivors | No patients developed CTRCD |
HOU ET AL. | GLS, GCS, GRS, GAS, | at 3 cycles of chemotherapy, | 3D GAS after three cycles of the chemotherapy group was significantly lower than that of the control group and changes in 3D GAS correlated with oxidative stress and apoptosis markers | No patients developed CTRCD |
KARAKULAK ET AL. | GLS, GCS, GAS and GRS | after imatinib failure and patient on dasatinib or nilotinib | significant reduction in 3D strain parameters in area with no difference between dasatinib and nilotinib groups. Additionally, area and radial strain had a stronger association with the duration of dasatinib treatment | No patients developed CTRCD |
LI. ET AL. | GLS, GCS, GRS, GAS, EF | survivors off treatment for 16.0 ± 6.1 years | all 3D strain parameters were significantly reduced in cancer survivors and GLS is considered the most sensitive parameter in the detection of subclinical cardiotoxicity | No patients developed CTRCD |
MIHALCEA ET AL. | GLS, GCS, GAS and GRS | at baseline, after third cycle and chemotherapy completion | 3D strain echocardiography showed a significant decrease of all deformation parameters LS, CS, RS, and AS in the study group after 3rd cycle and persistent after final cycle of therapy, with more important reduction in patient who developed cardiotoxicity. LS were identified as the best independent predictors for 3D LVEF decrease at the end of chemotherapy | 18 patients (16%) (group I) developed cardiotoxicity |
MIYOSHI. T ET AL. | GLS, GCS, GRS and GAS | anthracycline treated patients 13 ± 22 months after treatment | Only 3D-GAS and peak 3D global circumferential strains of the anthracycline group were significantly worse than those of the control group and 3D GAS was the only parameter that could be independently linked to the cumulative doxorubicin dose | No patients developed CTRCD |
MORNOS C ET AL. | GLS, GCS and GRS | before, and at 12 weeks after anthracycline treatment | 3D GLS, 3D GCS, and 3D GRS revealed significant changes 12 weeks after chemotherapy and 3D GLS emerged as the only independent predictor of later cardiotoxicity | Eight patients (13.5%) developed cardiotoxicity |
PIVETA. R ET AL. | GLS, GRS, GAS, GCS, rotation, torsion, and twist | baseline, after 120 mg &240 mg of doxorubicin, after 6 and 12 months | After a lower cumulative dose of doxorubicin (120 mg/m2), 3D GAS was the only parameter that was changed and was associated with a subsequent decrease in LVEF. while most myocardial deformation parameters: 3D GLS, 3D GRS and 3D GCS significantly changed after the cumulative dose of 240 mg/m2 of doxorubicin and no changes in rotation, torsion, or twist in any of the evaluation stages, | (13%) 7 patients presented developed significant decrease in LVEF during follow up |
SANTORO ET AL. | GLS, GCS, GAS and GRS | before and after completion of ANT chemotherapy | all 3D strain parameters were significantly reduced after chemotherapy with the greatest effect for GCS and GAS | No patients developed CTRCD |
SONG F ET AL. | Apical and basal rotation, twist and torsion | baseline, 2, and 4 cycles | 3D LV apical rotation, basal rotation, twist, and torsion declined progressively during the whole procedure (baseline vs. two and four cycles of the regimen | No patients developed CTRCD |
SONG F ET AL. | GLS, and GCS and RV GLS | baseline, 4 cycles and at the end | 3D GLS and GCS of LV and GLS of RV decreased significantly after four cycles of the therapy | No patients developed CTRCD |
WANG ET AL. | RV GLS, RV GCS, RV GRS and RV GAS | before and after completion of chemotherapy | RV GLS and RV GAS were significantly reduced after chemotherapy | No patients developed CTRCD |
WANG, Y. ET AL. | GLS, GCS, GRS, GAS, MCI and LVtw | Baseline, and after 1, 6 and 12 cycles | 3D STE parameters GLS, GAS, MCI and LVtw decreased after the first cycle of chemotherapy. Increasing cumulative dose of mFOLFOX6 correlated with decreases in left ventricular MCI, GLS, GAS, GCS, GRS, and LVtw, with statistically significant differences between pre- and post-chemotherapy. In particular, the decrease in MCI was found to be the most significant | No patients developed CTRCD |
XU ET AL. | 3D-GLS, 3D-GCS, 3D-LS of all segments | baseline, after the completion of two cycles and four cycles of the regimen respectively | 3D-GLS reduced significantly after four cycles of anthracycline, 3d-GCS showed no significant changes during the whole study. All longitudinal strains in the middle and apical segments showed a significant decrease after four cycles with an early drop of apical anterior and septal wall LS after two cycles | No patients developed CTRCD |
XU ET AL. | GLS, RV GLS, and RV FW LS | at baseline, the end and 12 months after chemotherapy | 3D GLS of LV and GLS and FWLS of RV decreased significantly at 12 months after chemotherapy | (10.5%) 10 patients developed Subclinical CTRCD during follow-up. Compared to baseline |
ZHANG ET AL. | GCS, GLS, principal strain, twist, and torsion | before, during and annually after termination in patents received anthracycline and participants treated with trastuzumab underwent echocardiograms every 3 months during therapy and annually thereafter | After a median 2.1 years follow-up period they reported that 3D LVEF, GCS, and GLS, had initial decrement. In contrast, values for 3D twist and torsion plateaued at six months without substantial subsequent change 3DLVEF, GCS, GLS, and principal strain were associated with concurrent and subsequent changes in systolic function | No patients developed CTRCD |
ZHAO ET AL. | RVLFS and RVLSS LV GLS, LV GCS | baseline, 2, 4, and 6 cycles | 3D RV LFS and longitudinal septal strain LV GLS were statistically significant before and after 4 cycles of chemotherapy and only RV LFS was associated with subsequent RV cardiotoxicity with RVEF decline at the end of follow-up. However, RV LSS and LV GCS were only significantly decreased at T3 | 27 patients developed cardiotoxicity after 6 cycles of chemotherapy (T3) |